HEPA
Hepion Pharmaceuticals
HEPA
HEPA
Delisted
HEPA was delisted on the 12th of May, 2025.
16 hedge funds and large institutions have $2.43M invested in Hepion Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$66.1K |
| 2 |
VF
Virtu Financial
New York
|
+$41K |
| 3 |
JPMorgan Chase & Co
New York
|
+$3.61K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$369 |
Top Sellers
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$337K |
| 2 |
Morgan Stanley
New York
|
-$32.9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$16.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.97K |
